INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

02 5 2022 16:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

02 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

28 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia 

09 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

01 3 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

28 2 2022 16:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress

24 2 2022 07:30:01 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies

23 2 2022 08:00:02 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

17 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

03 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

06 1 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

05 1 2022 16:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

05 1 2022 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

20 12 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

13 12 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

22 11 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

05 11 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

04 11 2021 07:30:01 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

28 10 2021 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

21 10 2021 07:30:00 提供 Nasdaq GlobeNewswire